May 31, 2019 Conference


Anti-VEGF Nonresponders in Wet AMD

Mr. Jorge Arroyo, Beth Israel Deaconess Medical Center-HMS (Presenter)

Precis: Age-related macular degeneration (AMD) is a leading cause of irreversible vision impairment worldwide.  The current standard-of-care for patients with wet AMD typically includes regular intravitreal injections of anti-VEGF drugs which result in decreased subretinal exudation and stable or improved vision.1 Unfortunately, there still remains a small set of patients who either do not experience a reduction or experience an increase in subretinal exudation, either early (never demonstrate a response to treatment) or late (initial response to treatment with recurrence of subretinal exudation).2,3  We will present a pharmacokinetic and pathophysiologic framework upon which to better understand these challenging cases and more rationally consider other therapeutic options.